IndustryCompany release

Axsome third-quarter product revenue rises 52% to $259.7m as smoking cessation Phase 3 starts

🇺🇸 Axsome Therapeutics, Inc. (AXSM) · Mon 02 Nov 2026

Auvelity, Sunosi and Symbravo together generated $259.7m in the quarter, while the company narrowed its net loss to $12.9m and began a Phase 3 trial of AXS-05 in smoking cessation.

Axsome Therapeutics reported third-quarter 2026 results on 2 November, with net product revenue of $259.7 million, a 52% increase. The figure is the sum of sales from three marketed products.

Auvelity (dextromethorphan-bupropion) was the main contributor at $207.6 million. Sunosi added $48.2 million and Symbravo, the newest of the three, contributed $3.9 million.

The company's net loss narrowed to $12.9 million, and it ended the quarter with $313.9 million in cash. The summary available does not give comparative figures for the loss or cash position, so the extent of the improvement cannot be stated here.

Axsome also said it began the Phase 3 SUMMIT trial in August, testing AXS-05, the dextromethorphan-bupropion combination, for smoking cessation. Topline data are expected in the second half of 2027. Details of trial design, enrolment and endpoints were not available in the material reviewed.

What it means for your team

  • Market-access teams should note Auvelity's scale at $207.6m, which makes it the dominant driver of Axsome's commercial portfolio.
  • A smoking cessation indication for AXS-05 would be a new use of an existing combination; any future filing would depend on SUMMIT results due in the second half of 2027.
  • Pharmacovigilance and regulatory teams have no new safety or labelling information in this update; the trial's design details were not disclosed in the material reviewed.

Company's press release (SEC filing): Axsome Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Axsome Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →